U.S. patent application number 11/825045 was filed with the patent office on 2008-02-07 for inhibitors of advanced glycation end products.
Invention is credited to Raja G. Khalifah, Roger E. Marti.
Application Number | 20080032990 11/825045 |
Document ID | / |
Family ID | 38981956 |
Filed Date | 2008-02-07 |
United States Patent
Application |
20080032990 |
Kind Code |
A1 |
Khalifah; Raja G. ; et
al. |
February 7, 2008 |
Inhibitors of advanced glycation end products
Abstract
The present invention provides compounds of the formula,
##STR1## wherein A, B, G, R.sup.2, R.sup.6, and X are defined
herein, pharmaceutical compositions of the same, and methods for
treating or inhibiting development of AGE- and/or ALE-associated
complications in subjects in need thereof
Inventors: |
Khalifah; Raja G.; (Cary,
NC) ; Marti; Roger E.; (St. Hrsen, CH) |
Correspondence
Address: |
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO
IL
60606
US
|
Family ID: |
38981956 |
Appl. No.: |
11/825045 |
Filed: |
July 3, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60819437 |
Jul 7, 2006 |
|
|
|
Current U.S.
Class: |
514/252.18 ;
514/341; 544/357; 546/274.1 |
Current CPC
Class: |
A61P 9/12 20180101; A61P
9/10 20180101; A61P 19/04 20180101; C07D 405/14 20130101; A61P
19/02 20180101; A61P 9/00 20180101; A61P 3/06 20180101; A61P 3/10
20180101; C07H 17/02 20130101; C07D 401/14 20130101; C07D 401/04
20130101 |
Class at
Publication: |
514/252.18 ;
514/341; 544/357; 546/274.1 |
International
Class: |
A61K 31/4412 20060101
A61K031/4412; A61K 31/497 20060101 A61K031/497; C07D 401/04
20060101 C07D401/04; C07D 401/14 20060101 C07D401/14 |
Claims
1. A compound of the formula, ##STR15## or a pharmaceutically
acceptable salt thereof, wherein X is N, N--O, or CR.sup.1; G is
--H, heterocycle, or --(C.sub.1-C.sub.6)alkyl, wherein the
heterocycle and alkyl are optionally substituted with at least one
group independently selected from the group consisting of -halogen,
--OR.sup.G, --N(R.sup.G).sub.2, --SR.sup.G, --S(O)R.sup.G,
--S(O).sub.2R.sup.G, --COOR.sup.G, --CON(R.sup.G).sub.2, and
--(C.sub.1-C.sub.6)alkyl-OR.sup.G, wherein R.sup.G is hydrogen,
--(C.sub.1-C.sub.6)alkyl, or --C(O)(C.sub.1-C.sub.6)alkyl; A is of
the formula, ##STR16## wherein Y is N or N-oxide; and ring C is:
(i) monocyclic; (ii) saturated; and (iii) contains 1 or 2 total
heteroatoms, and 5 or 6 total atoms, wherein the remaining
heteroatom moiety is O, S, or NR.sup.N1, and the carbon atoms are
each optionally substituted with one or two R.sup.C wherein
R.sup.N1 is --H, -oxide, --C.sub.1-C.sub.6)alkyl,
--C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycle, -aryl, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl, -aroyl,
-heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N1 is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N12, --N(R.sup.N12).sub.2,
--COOR.sup.N12, --CON(R.sup.N12).sub.2, --SR.sup.N12,
--S(O)R.sup.N12, --S(O).sub.2R.sup.N12, --NO.sub.2, --CN,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)alkyl-OR.sup.N12,
-aryl, --(C.sub.1C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl, wherein R.sup.N12 is
hydrogen, --(C.sub.1-C.sub.6)alkyl, or
--C(O)(C.sub.1-C.sub.6)alkyl; each R.sup.C is independently
-Z.sup.1-M-Z.sup.2-R.sup.Z, wherein M is --C(O)--, --C(S)--,
--S(O)--, --S(O).sub.2--, or absent, provided when M is --S(O)--,
--S(O)--, or absent, at least one of Z.sup.1 and Z.sup.2 is also
absent; Z.sup.1 and Z.sup.2 are independently --O--, --S--,
--N(R.sup.N')--, or absent, wherein R.sup.N' is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl,
--(C.sub.1-C.sub.6)alkynyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycle, -aryl, -heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl,
-heterocycloyl, -aroyl, -heteroaroyl,
--(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR, --COOR, --CONR.sub.2, --SR, --S(O)R,
--S(O).sub.2R, --NR.sub.2, --NO.sub.2, --CN,
--(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl wherein each R is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'; wherein each R' is independently halogen,
--OR'', --CN, --COR'', --COOR'', --CONR''.sub.2, NR''.sub.2,
wherein each R'' is independently --H, --(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl; R.sup.Z is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl,
--(C.sub.1-C.sub.6)alkynyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z is optionally
substituted with at least one R.sup.Z', wherein each R.sup.Z is
independently -halogen, --OR, --(C.sub.1-C.sub.6)alkoxy, --C(O)OR,
--C(O)R, --C(O)NR.sub.2, --S(O).sub.2R, --OS(O).sub.2R, -cyano,
-nitro,--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, or heteroaryl,
wherein R.sup.Z' is optionally substituted with one or more R', or
any two R.sup.C attached to the same carbon, taken together, is oxo
or .dbd.N(R.sup.N4), wherein R.sup.N4 is --H, --OR,
--N(R.sup.N5).sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycle, -aryl, or -heteroaryl,
wherein R.sup.N4 is optionally substituted with one or more groups
which are independently -halogen, --OH, -amino,
--(C.sub.1-C.sub.6)alkylamino, --(C.sub.1-C.sub.6)dialkylamino,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heteroaryl,
-heterocycle, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl; and each R.sup.N5 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl, or
--(C.sub.3-C.sub.8)cycloalkyl; B is of the formula, ##STR17##
wherein ring D is (i) monocyclic, and (ii) saturated, unsaturated,
or aromatic; R.sup.C' is R.sup.C, provided that R.sup.C' is not
aryl or heteroaryl; G.sup.1, G.sup.2, and G.sup.3 each are
independently N, O, CR.sup.3, C(R.sup.3).sub.2, or NR.sup.N',
wherein each R.sup.3 is independently -Z.sup.3-M-Z.sup.4-R.sup.Z,
provided when M is --S(O)--, --S(O)--, or absent, at least one of
Z.sup.3 and Z.sup.4 is also absent; Z.sup.3 and Z.sup.4 are
independently --O--, --S--, --N(R.sup.N3)-- or absent, wherein
R.sup.N3 is --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl, -aroyl,
-heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N3 is
optionally substituted with one or more groups which are
independently -halogen, --OH, -amino,
--(C.sub.1-C.sub.6)alkylamino, --(C.sub.1-C.sub.6)dialkylamino,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl; or two R.sup.3 taken
together are oxo; and bonds a, b, c, d, and e are independently a
single or double bond, provided that (i) no two consecutive atoms
in ring D are both oxygen; (ii) no two consecutive bonds are both
double bonds; (iii) if a or b is a double bond, then R.sup.C' is
absent; and (iv) if a or e is a double bond, then R.sup.N' is
absent; and R.sup.1, R.sup.2, and R.sup.6 are independently --H,
-halogen, --NO.sub.2, --CN, or R.sup.C, provided that when
X.dbd.CR.sup.1, (i) R.sup.2, R.sup.6, and R.sup.N1 are not phenyl;
(ii) R.sup.C is not aryl, heteroaryl, heterocycle, or
(C.sub.2-C.sub.6)alkenyl (iii) and G.sup.1.dbd.N together, then
G.sub.2 is not O; and (iv) two R.sup.C together may not form oxo;
and provided that when X.dbd.N, and (i) G.sup.1 and G.sup.3each are
CR.sup.3, G.sup.2.dbd.N, and bonds b and d are each a double bond,
all simultaneously; or (ii) G.sup.1 is CR.sup.3, G.sup.3 is C(O),
G.sup.2 is NR.sup.N', and bond b is a double bond, all
simultaneously; either R.sup.2 or R.sup.6 is not --NH-aryl or
--NH-heteroaryl.
2. The compound according to claim 1, wherein X is N and G is
hydrogen.
3. The compound according to claim 2, wherein B is aromatic; and
G.sup.1, G.sup.2, and G.sup.3 are each independently O, N or
CR.sup.3.
4. The compound according to claim 3, wherein B is imidazolyl,
oxazoyl, pyrazoyl, pyrroyl, or isoxazoyl wherein each carbon atom
is substituted by R.sup.3.
5. The compound according to claim 4, wherein B is imidazolyl
wherein each carbon atom is substituted by R.sup.3.
6. The compound according to claim 5, wherein each R.sup.3 is
independently R.sup.Z3, wherein R.sup.Z3 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z3 is optionally
substituted with at least one R.sup.Z3', wherein each R.sup.Z3 is
independently -halogen, -cyano, --OR, --C(O)OR, --C(O)R,
--C(O)NR.sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl, or
-heterocycloalkyl.
7. The compound according to claim 5, wherein R.sup.2 and R.sup.6
are each --H, -halogen, --NO.sub.2, --CN, or --R.sup.Z6 wherein
R.sup.Z6 is --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6 is optionally
substituted with at least one R.sup.Z6', wherein each R.sup.Z6' is
independently -halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, wherein
R.sup.Z6' is optionally substituted with one or more R'.
8. The compound according to claim 5, wherein R.sup.N' is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl, -aryl,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl,
-aroyl, -heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.N''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl, or
--(C.sub.1-C.sub.6)haloalkyl, wherein each R.sup.N'' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
9. The compound according to claim 5, wherein ring C contains 2
heteroatoms, and 5 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
10. The compound according to claim 5, wherein ring C contains 2
heteroatoms, and 6 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
11. The compound according to claim 2, wherein B is not aromatic
and G.sup.1, G.sup.2, and G.sup.3 are each independently O, N,
CR.sup.3,C(R.sup.3).sub.2, or N(R.sup.N').
12. The compound according to claim 12, wherein B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'.
13. The compound according to claim 12, wherein each R.sup.3 is
independently R.sup.Z3, wherein R.sup.Z3 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z3 is optionally
substituted with at least one R.sup.Z3', wherein each R.sup.Z3' is
independently -halogen, -cyano, --OR, --C(O)OR, --C(O)R,
--C(O)NR.sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl, or
-heterocycloalkyl.
14. The compound according to claim 12, wherein R.sup.2 and R.sup.6
are each --H, -halogen, --NO.sub.2, --CN, or --R.sup.Z6 wherein
R.sup.Z6 is --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6 is optionally
substituted with at least one R.sup.Z6', wherein each R.sup.Z6' is
independently -halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, wherein
R.sup.Z6' is optionally substituted with one or more R'.
15. The compound according to claim 12, wherein each R.sup.N' is
--H, --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl, -aryl,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl,
-aroyl, -heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.N''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl, or
--(C.sub.1-C.sub.6)haloalkyl, wherein each R.sup.N'' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
16. The compound according to claim 12, wherein ring C contains 2
heteroatoms, and 5 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
17. The compound according to claim 12, wherein ring C contains 2
heteroatoms, and 6 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
18. The compound according to claim 1, wherein X is CR.sup.1 and G
is hydrogen.
19. The compound according to claim 18, wherein R.sup.1is --N,
--NO.sub.2, -halogen, --C(O)OR.sup.4, --C(O)R.sup.4,
--C(O)N(R.sup.4).sub.2, --S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein each R.sup.4is independently
--H, --(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.4 is optionally
substituted with at least one group, each of which are
independently -halogen, --OH, --(C.sub.1-C.sub.6)alkoxy,
--C(O)R.sup.41, --S(O).sub.2R.sup.41, --OS(O).sub.2R.sup.41,
-cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl.
20. The compound according to claim 19, wherein B is aromatic; and
G.sup.1, G.sup.2, and G.sup.3 are each independently O, N or
CR.sup.3.
21. The compound according to claim 20, wherein B is imidazolyl,
oxazoyl, pyrazoyl, pyrroyl, or isoxazoyl wherein each carbon atom
is substituted by R.sup.3.
22. The compound according to claim 21, wherein B is imidazolyl
wherein each carbon atom is substituted by R.sup.3.
23. The compound according to claim 22, wherein each R.sup.3 is
independently R.sup.Z3, wherein R.sup.Z3 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z3 is optionally
substituted with at least one R.sup.Z3', wherein each R.sup.Z3' is
independently -halogen, -cyano, --OR, --C(O)OR, --C(O)R,
--C(O)NR.sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl, or
-heterocycloalkyl.
24. The compound according to claim 22, wherein R.sup.2 and R.sup.6
are each --H, -halogen, --NO.sub.2, --CN, or --R.sup.Z6 wherein
R.sup.Z6 is --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6 is optionally
substituted with at least one R.sup.Z6', wherein each R.sup.Z6' is
independently -halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, wherein
R.sup.Z6' is optionally substituted with one or more R'.
25. The compound according to claim 22, wherein R.sup.N' is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl, -aryl,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl,
-aroyl, -heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.N''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl, or
--(C.sub.1-C.sub.6)haloalkyl, wherein each R.sup.N'' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
26. The compound according to claim 22, wherein ring C contains 2
heteroatoms, and 5 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R'.
27. The compound according to claim 22, wherein ring C contains 2
heteroatoms, and 6 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
28. The compound according to claim 19, wherein B is not aromatic
and G.sup.1, G.sup.2, and G.sup.3 are each independently O, N,
CR.sup.3,C(R.sup.3).sub.2, or N(R.sup.N').
29. The compound according to claim 28, wherein B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'.
30. The compound according to claim 29, wherein each R.sup.3 is
independently R.sup.Z3, wherein R.sup.Z3 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z3 is optionally
substituted with at least one R.sup.Z3', wherein each R.sup.Z3' is
independently -halogen, -cyano, --OR, --C(O)OR, --C(O)R,
--C(O)NR.sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl, or
-heterocycloalkyl.
31. The compound according to claim 29, wherein R.sup.2 and R.sup.6
are each --H, -halogen, --NO.sub.2, --CN, or --R.sup.Z6 wherein
R.sup.Z6 is --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6 is optionally
substituted with at least one R.sup.Z6', wherein each R.sup.Z6' is
independently -halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, wherein
R.sup.Z6' is optionally substituted with one or more R'.
32. The compound according to claim 29, wherein each R.sup.N' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkyl, -aryl, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl, -aroyl,
-heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.N''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl, or
--(C.sub.1-C.sub.6)haloalkyl, wherein each R.sup.N'' is
independently --, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
33. The compound according to claim 29, wherein ring C contains 2
heteroatoms, and 5 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
34. The compound according to claim 29, wherein ring C contains 2
heteroatoms, and 6 total atoms, wherein the remaining heteroatom
moiety is O, S, or NR.sup.N1, and the carbon atoms are each
optionally substituted with one or two R.sup.C.
35. The compound according to claim 1 which is
4-(1H-imidazol-2-yl)-2-methyl-5-((4-methylpiperazin-1-yl)methyl)pyridin-3-
-ol.
36. A pharmaceutical composition comprising the compound of claim 1
and a pharmaceutically acceptable carrier.
37. A method for treating or inhibiting development of one or more
AGE- and/or ALE-associated complications in subject in need thereof
comprising administering one or more compounds according to claim 1
to the subject.
38. A method for treating or inhibiting development of one or more
AGE- and/or ALE-associated complications in a subject in need
thereof comprising administering one or more pharmaceutical
compositions according to claim 26 to the subject.
39. The method of claim 37 wherein the one or more AGE- and/or
ALE-associated complications are selected from the group consisting
of accelerated protein aging, retinopathy, nephropathy,
proteinuria, impaired glomerular clearance, neuropathy,
hyperlipidemia, hypertriglyceridemia, hypercholesterolemia,
atherosclerosis, cardiovascular disease, neurodegenerative amyloid
diseases, diabetes-associated hyperlipidemia, oxidative
modification of proteins, arthritis, connective tissue diseases,
amyloidosis, urinary stone disease, obesity-related complications,
proliferation of smooth muscle cells in the aorta, coronary artery
occlusion, hypertension; and dialysis-related disorders selected
from the group consisting of dialysis-related cardiac morbidity and
mortality, dialysis-related amyloidosis, dialysis-related increases
in permeability of the peritoneal membrane in a dialysis patient,
renal failure progression in a dialysis patient, and
ultrafiltration failure and peritoneal membrane destruction in a
dialysis patient.
40. A method for treating or inhibiting development of one or more
disorders selected from the group consisting of diabetic
nephropathy, proteinuria, impaired glomerular clearance,
retinopathy, neuropathy, atherosclerosis, diabetes-associated
hyperlipidemia, oxidative modification of proteins, arthritis,
connective tissue diseases, amyloidosis, urinary stone disease,
obesity-related complications proliferation or smooth muscle cells
in the aorta, coronary artery occlusion, and hypertension; and
dialysis-related disorders including dialysis-related cardiac
morbidity and mortality, dialysis-related amyloidosis,
dialysis-related increases in permeability of the peritoneal
membrane in a dialysis patient, renal failure progression in a
dialysis patient, and inhibiting ultrafiltration failure and
peritoneal membrane destruction in a dialysis patient, wherein the
method comprises administering an effective amount of a compound
according to claim 1 to a subject in need of such treatment.
41. A method for treating or inhibiting development of one or more
disorders selected from the group consisting of diabetic
nephropathy, proteinuria, impaired glomerular clearance,
retinopathy, neuropathy, atherosclerosis, diabetes-associated
hyperlipidemia, oxidative modification of proteins, arthritis,
connective tissue diseases, amyloidosis, urinary stone disease,
obesity-related complications proliferation or smooth muscle cells
in the aorta, coronary artery occlusion, and hypertension; and
dialysis-related disorders including dialysis-related cardiac
morbidity and mortality, dialysis-related amyloidosis,
dialysis-related increases in permeability of the peritoneal
membrane in a dialysis patient, renal failure progression in a
dialysis patient, and inhibiting ultrafiltration failure and
peritoneal membrane destruction in a dialysis patient, wherein the
method comprises administering an effective amount of a
pharmaceutical composition according to claim 36 to a subject in
need of such treatment.
Description
CROSS-REFERENCE
[0001] This application claims priority to U.S. Provisional Patent
Application Ser. No. 60/819,437 filed Jul. 7, 2006, incorporated by
reference herein in its entirety.
FIELD OF THE INVENTION
[0002] This application relates to the fields of chemistry,
medicine, renal disease, vascular disease, hyperlipidemia,
hyperglycemia, advanced glycation end-products, and advanced
lipoxidation end-products.
BACKGROUND OF THE INVENTION
[0003] Advanced glycation end-products (AGEs) are
carbohydrate-derived chemical modifications and crosslinks that
accumulate in long-lived tissue proteins during normal aging. The
increased rate of accumulation of AGEs during hyperglycemia is
implicated in the development of long-term complications of
diabetes, including but not limited to retinopathy, nephropathy,
neuropathy, atherosclerosis, and cardiovascular disease. In
addition, AGE formation has been implicated in a number of other
pathologies, such as normal aging processes, arthritis, connective
tissue disease, amyloidoses, and neurodegenerative amyloid
diseases, such as Alzheimer's.
[0004] Advanced lipoxidation end products (ALEs) are lipid-derived
chemical modifications and crosslinks that also accumulate in
long-lived tissue proteins during normal aging, and are associated
with hyperlipidemia, vascular disease, and renal disease in both
diabetic and non-diabetic animal models. It is now recognized that
some compounds, such as N.sup..epsilon.-(carboxymethyl)lysine (CML)
and N.sup..epsilon.-(carboxyethyl)lysine (CEL), may be derived from
either carbohydrates or lipids, leading to their designation as
AGE/ALEs. Other compounds, such as pentosidine, appear to be true
AGEs, while other compounds, such as malondialdehyde-lysine
(MDA-Lys) and hydroxynonenal-lysine (HNE-Lys), are acknowledged to
be ALEs, derived exclusively from lipids.
[0005] The elucidation of the pathogenic mechanisms of AGE and
ALE-associated complications associated with hyperglycemia and/or
hyperlipidemia is critical for developing rational therapy for
their treatment and prevention. However, there is no consensus at
present on the relative importance of the different possible
pathogenic mechanisms that potentially contribute to these diabetic
complications.
[0006] The compound pyridoxamine has recently been shown to inhibit
both AGE and ALE formation in vitro, and to be useful for treating
and preventing AGE and ALE-associated complications in
hyperglycemic, hyperlipidemic, and hyperglycemic-hyperlipidemic
animal models. (See, for example, U.S. Pat. Ser. No. 5,985,857; WO
00/21516; WO 00/23063) Such complications include, but are not
limited to, diabetic nephropathy, proteinuria, impaired glomerular
clearance, retinopathy, neuropathy, atherosclerosis,
diabetes-associated hyperlipidemia, oxidative modification of
proteins, urinary stone disease, obesity-related complications,
proliferation or smooth muscle cells in the aorta, coronary artery
occlusion, and hypertension; and dialysis-related disorders
including dialysis-related cardiac morbidity and mortality,
dialysis-related amyloidosis, dialysis-related increases in
permeability of the peritoneal membrane in a dialysis patient,
renal failure progression in a dialysis patient, and inhibiting
ultrafiltration failure and peritoneal membrane destruction in a
dialysis patient.
[0007] However, there remains a need in the art for further options
to treat or inhibit development of AGE- and ALE-associated
complications in patients in need thereof, particularly patients
with hyperglycemia and/or hyperlipidemia.
SUMMARY OF THE INVENTION
[0008] The present invention provides compounds, pharmaceutical
compositions, and methods for treating or inhibiting development of
AGE- and/or ALE-associated complications in a subject in need
thereof. Thus, the invention provides novel compounds, detailed
below, and pharmaceutical compositions thereof In a preferred
embodiment, the methods comprise administering one or more of the
compounds or pharmaceutical compositions of the invention to
subjects suffering from hyperglycemia and/or hyperlipidemia. The
invention further comprises methods of treating or inhibiting
development of disorders including diabetic nephropathy,
proteinuria, impaired glomerular clearance, retinopathy,
neuropathy, atherosclerosis, diabetes-associated hyperlipidemia,
oxidative modification of proteins, arthritis, connective tissue
diseases, amyloidosis, urinary stone disease, obesity-related
complications, proliferation of smooth muscle cells in the aorta,
coronary artery occlusion, and hypertension; and dialysis-related
disorders including dialysis-related cardiac morbidity and
mortality, dialysis-related amyloidosis, dialysis-related increases
in permeability of the peritoneal membrane in a dialysis patient,
renal failure progression in a dialysis patient, and inhibiting
ultrafiltration failure and peritoneal membrane destruction in a
dialysis patient. Said methods comprise administering an effective
amount of one or more compounds of the present invention, or a
pharmaceutically acceptable salt thereof, to a subject in need of
such treatment.
BRIEF DESCRIPTION OF THE FIGURES
[0009] FIG. 1 illustrates the chemical structures for several
compounds referenced herein.
[0010] FIG. 2 is a graphical representation providing comparative
cell toxicity data for pyridoxamine (PM), BST-4997, BST-998,
BST-146, BST-605.
[0011] FIG. 3 is a graphical representation of the effect of
BST-605 on the restoration of nerve conduction velocity in motor
(sciatic nerve) neurons in streptozotocin diabetic rats.
[0012] FIG. 4 is a graphical representation of the effect of
BST-605 on the restoration of nerve conduction velocity in sensory
(saphenous) neurons in streptozotocin diabetic rats.
[0013] FIG. 5 is a graphical comparison of the effect of BST-605,
BST-4997, and pyridoxamine on the restoration of nerve conduction
velocity in motor (sciatic nerve) neurons in streptozotocin
diabetic rats.
DETAILED DESCRIPTION OF THE INVENTION
[0014] In a first aspect, the invention provides the compound of
formula (I), ##STR2## or a pharmaceutically acceptable salt
thereof, wherein [0015] X is N, N--O, or CR.sup.1; [0016] G is --H,
heterocycle, or --(C.sub.1-C.sub.6)alkyl, wherein the heterocycle
and alkyl are optionally substituted with at least one group
independently selected from the group consisting of -halogen,
--OR.sup.G, --N(R.sup.G).sub.2, --SR.sup.G, --S(O)R.sup.G,
--S(O).sub.2R.sup.G, --COOR.sup.G, --CON(R.sup.G).sub.2, and
--(C.sub.1-C.sub.6)alkyl-OR.sup.G, wherein R.sup.G is hydrogen,
--(C.sub.1-C.sub.6)alkyl, or --C(O)(C.sub.1-C.sub.6)alkyl; [0017] A
is of formula (1a), ##STR3## wherein [0018] Y is N or N-oxide; and
[0019] ring C is: [0020] (i) monocyclic; [0021] (ii) saturated; and
[0022] (iii) contains 1 or 2 total heteroatoms, and 5 or 6 total
atoms, wherein [0023] the remaining heteroatom moiety is O, S, or
NR.sup.N1, and the carbon atoms are each optionally substituted
with one or two R.sup.C wherein [0024] R.sup.N1 is --H, -oxide,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl, [0025]
--(C.sub.1-C.sub.6)alkynyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycle, -aryl, -heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl,
-heterocycloyl, -aroyl, -heteroaroyl,
--(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0026] R.sup.N1 is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N12, --N(R.sup.12).sub.2,
--COOR.sup.N12, --CON(R.sup.N12).sub.2, --SR.sup.N12,
--S(O)R.sup.N.sup.12, --S(O).sub.2R.sup.N.sup.12, --NO.sub.2, --CN,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)alkyl-OR.sup.N12,
-aryl, --(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl, wherein R.sup.N12 is
hydrogen, --(C.sub.1-C.sub.6)alkyl, or
--C(O)(C.sub.1-C.sub.6)alkyl; [0027] each R.sup.C is independently
-Z.sup.1-M-Z.sup.2-R.sup.Z, wherein [0028] M is --C(O)--, --C(S)--,
--S(O)--, --S(O)--, or absent, [0029] provided when M is --S(O)--,
--S(O).sub.2--, or absent, at least one of Z.sup.1 and Z.sup.2 is
also absent; [0030] Z.sup.1 and Z.sup.2 are independently --O--,
--S--, --N(R.sup.N')--, or absent, wherein [0031] R.sup.N' is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl,
--(C.sub.1-C.sub.6)alkynyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycle, -aryl, -heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl,
-heterocycloyl, -aroyl, -heteroaroyl,
--(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0032] R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR, --COOR, --CONR.sub.2, --SR, --S(O)R,
--S(O).sub.2R, --NR.sub.2, --NO.sub.2, --CN,
--(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl [0033] wherein each R is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'; [0034] wherein each R' is independently
halogen, --OR'', --CN, --COR'', --COOR'', --CONR''.sub.2, or
NR''.sub.2, wherein [0035] each R'' is independently --H,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl; [0036]
R.sup.Z is --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0037] R.sup.Z is optionally substituted with at least one
R.sup.Z', wherein [0038] each R.sup.Z' is independently -halogen,
--OR, --(C.sub.1-C.sub.6)alkoxy, --C(O)OR, --C(O)R, --C(O)NR.sub.2,
--S(O).sub.2R, --OS(O).sub.2R, -cyano,
-nitro,--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, or heteroaryl,
[0039] wherein R.sup.Z' is optionally substituted with one or more
R', [0040] or any two R.sup.C attached to the same carbon, taken
together, is oxo or .dbd.N(R.sup.N4), wherein [0041] R.sup.N4 is
--H, --OR, --N(R.sup.N5).sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycle, -aryl, or -heteroaryl,
wherein [0042] R.sup.N4 is optionally substituted with one or more
groups which are independently -halogen, --OH, -amino,
--(C.sub.1-C.sub.6)alkylamino, --(C.sub.1-C.sub.6)dialkylamino,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heteroaryl,
-heterocycle, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.1-C.sub.6)alkanoyl, or -aroyl; and [0043] each R.sup.N5 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, --(C.sub.1-C.sub.6)alkynyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl, or
--(C.sub.3-C.sub.8)cycloalkyl; B is of formula (Ib), ##STR4##
wherein [0044] ring D is (i) monocyclic, and [0045] (ii) saturated,
unsaturated, or aromatic; [0046] R.sup.C' is R.sup.C, provided that
R.sup.C' is not aryl or heteroaryl; [0047] G.sup.1, G.sup.2, and
G.sup.3 each are independently N, O, CR.sup.3, C(R).sub.2, or
NR.sup.N', wherein [0048] each R.sup.3 is independently
-Z.sup.3-M-Z.sup.4-R.sup.Z, [0049] provided when M is --S(O)--,
--S(O).sub.2--, or absent, at least one of Z.sup.3 and Z.sup.4 is
also absent; [0050] Z.sup.3 and Z.sup.4 are independently --O--,
--S--, --N(R.sup.N3)-- or absent, wherein [0051] R.sup.N3 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl,
--(C.sub.1-C.sub.6)alkynyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkanoyl,
-heterocycloyl, -aroyl, -heteroaroyl,
--(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0052] R.sup.N3 is
optionally substituted with one or more groups which are
independently -halogen, --OH, -amino, --(C.sub.1-.sub.6)alkylamino,
--(C.sub.1-C.sub.6)dialkylamino, --NO.sub.2, --CN,
--(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.1-C.sub.6)alkanoyl, or -aroyl;
[0053] or two R.sup.3 taken together are oxo; and [0054] bonds a,
b, c, d, and e are independently a single or double bond, provided
that [0055] (i) no two consecutive atoms in ring D are both oxygen;
[0056] (ii) no two consecutive bonds are both double bonds; [0057]
(iii) if a or b is a double bond, then R.sup.C' is absent; and
[0058] (iv) if a or e is a double bond, then R.sup.N' is absent;
and [0059] R.sup.1, R.sup.2, and R.sup.6 are independently --H,
-halogen, --NO.sub.2, --CN, or R.sup.C, provided that when
X.dbd.CR.sup.1, [0060] (i) R.sup.2, R.sup.6, and R.sup.N1 are not
phenyl; [0061] (ii) R.sup.C is not aryl, heteroaryl, heterocycle,
or (C.sub.2-C.sub.6)alkenyl [0062] (iii) and G.sup.1=N together,
then G.sup.2 is not O; and [0063] (iv) two R.sup.C together may not
form oxo; and provided that when X.dbd.N, and [0064] (i) G.sup.1
and G.sup.3 each are CR.sup.3, G.sup.2=N, and bonds b and d are
each a double bond, all simultaneously; or [0065] (ii) G.sup.1 is
CR.sup.3, G.sup.3 is C(O), G.sup.2 is NR.sup.N', and bond b is a
double bond, all simultaneously; [0066] either R.sup.2 or R.sup.6
is not --NH-aryl or --NH-heteroaryl.
[0067] In a preferred embodiment, the invention provides the
compound according to formula (I) wherein G is hydrogen.
[0068] In a preferred embodiment, the invention provides the
compound according to formula (I) wherein G is a heterocycle or
--(C.sub.1-C.sub.6)alkyl, each optionally substituted with at least
one group independently selected from the group consisting of
--OR.sup.G, --N(R.sup.G).sub.2, --SR.sup.G, --S(O)R.sup.G,
--S(O)R.sup.G, --COOR.sup.G, --CON(R.sup.G).sub.2, and
--(C.sub.1-C.sub.6)alkyl-OR.sup.G, wherein R.sup.G is hydrogen,
--(C.sub.1-C.sub.6)alkyl, or --C(O)(C.sub.1-C.sub.6)alkyl.
[0069] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N.
[0070] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; and G is --H.
[0071] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; and G is a heterocycle or
--(C.sub.1-C.sub.6)alkyl, each optionally substituted with at least
one group independently selected from the group consisting of
--OR.sup.G, --N(R.sup.G).sub.2, --SR.sup.G, --S(O)R.sup.G,
--S(O).sub.2R.sup.G, --COOR.sup.G, --CON(R.sup.G).sub.2, and
--(C.sub.1-C.sub.6)alkyl-OR.sup.G, wherein R.sup.G is hydrogen,
--(C.sub.1-C.sub.6)alkyl, or --C(O)(C.sub.1-C.sub.6)alkyl.
[0072] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; and G is a heterocycle or
--(C.sub.1-C.sub.6)alkyl, each optionally substituted with at least
one group independently selected from the group consisting of --OH
and --COOH.
[0073] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; and G is a
tetrahydrofuranyl, tetrahydropyranyl, or --(C.sub.5-C.sub.6)alkyl,
each optionally substituted with at least one group independently
selected from the group consisting of --OH and --COOH.
[0074] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N--O.
[0075] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; B is
aromatic; and [0076] G.sup.1, G.sup.2, and G.sup.3 are each
independently O, N or CR.sup.3.
[0077] In preferred embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; and [0078]
B is imidazolyl, oxazoyl, pyrazoyl, pyrroyl, or isoxazoyl wherein
each carbon atom is substituted by R.sup.3.
[0079] In more preferred embodiment, the invention provides the
compound according to formula (I), wherein X is N; G is hydrogen;
and [0080] B is imidazolyl, wherein each carbon atom is substituted
by R.sup.3.
[0081] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0082] B
is imidazolyl, wherein each carbon atom is substituted by R.sup.3;
and [0083] wherein each R.sup.3 is independently R.sup.23, wherein
[0084] R.sup.Z3 is --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylary, -heterocycle, -aryl, or -heteroaryl,
wherein R.sup.23 is optionally substituted with at least one
R.sup.Z3', wherein [0085] each R.sup.Z3' is independently -halogen,
-cyano, --OR, --C(O)OR, --C(O)R, --C(O)NR.sub.2,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, or -heterocycloalkyl.
[0086] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0087] B
is imidazolyl, wherein each carbon atom is substituted by R.sup.3;
and [0088] R.sup.2 and R.sup.6 are each --H, -halogen, --NO.sub.2,
--CN, or --R.sup.Z6 wherein [0089] R.sup.Z6 is
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6', is
optionally substituted with at least one R.sup.Z6', [0090] wherein
each R.sup.Z6' is independently halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, [0091]
wherein R.sup.Z6' is optionally substituted with one or more
R'.
[0092] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0093] B
is imidazolyl, wherein each carbon atom is substituted by R.sup.3;
and [0094] R.sup.N' is --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkyl, -aryl, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl, -aroyl,
-heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0095] R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.N''.sub.2, --NO,
--CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkyl, or --(C.sub.1-C.sub.6)haloalkyl,
[0096] wherein each R.sup.N'' is independently --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl, wherein the alkyl and
alkoxy are optionally substituted with one or more R'.
[0097] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0098] B
is imidazolyl, wherein each carbon atom is substituted by R.sup.3;
[0099] Y is N; and [0100] ring C contains 2 heteroatoms, and 5
total atoms, wherein [0101] the remaining heteroatom moiety is O,
S, or NR.sup.N1, and the carbon atoms are each optionally
substituted with one or two R.sup.C.
[0102] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0103] B
is imidazolyl, wherein each carbon atom is substituted by R.sup.3;
[0104] Y is N; and [0105] ring C contains 2 heteroatoms, and 6
total atoms, wherein [0106] the remaining heteroatom moiety is O,
S, or NR.sup.N1, and the carbon atoms are each optionally
substituted with one or two R.sup.C.
[0107] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0108] B
is not aromatic; and [0109] G.sup.1, G.sup.2, and G.sup.3 are each
independently O, N, CR.sup.3,C(.sup.3).sub.2, or N(R.sup.N').
[0110] In a preferred embodiment, the invention provides the
compound according to formula (I), wherein X is N; G is hydrogen;
[0111] B is pyrrolidinyl, pyrazolidinyl, imidazolidinyl,
isoxazolidinyl, oxazolidinyl, triazolidinyl, or tetrazolidinyl,
wherein [0112] each carbon is substituted by two R.sup.3 and each
nitrogen is substituted by R.sup.N'.
[0113] In a more preferred embodiment, the invention provides the
compound according to formula (I), wherein X is N; G is hydrogen;
[0114] B is pyrrolidinyl, pyrazolidinyl, imidazolidinyl,
isoxazolidinyl, oxazolidinyl, triazolidinyl, or tetrazolidinyl,
wherein [0115] each carbon is substituted by two R.sup.3 and each
nitrogen is substituted by R.sup.N'; and [0116] each R.sup.3 is
independently R.sup.Z3, wherein [0117] R.sup.Z3 is --H,
--(C.sub.1-C.sub.6)allyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z3 is optionally
substituted with at least one R.sup.Z3', wherein [0118] each
R.sup.Z3' is independently -halogen, -cyano, --OR, --C(O)OR,
--C(O)R, --C(O)NR.sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl, or
-heterocycloalkyl.
[0119] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0120] B
is pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl,
oxazolidinyl, triazolidinyl, or tetrazolidinyl, wherein [0121] each
carbon is substituted by two R.sup.3 and each nitrogen is
substituted by R.sup.N'; and [0122] R.sup.2 and R.sup.6 are each
--H, -halogen, --NO.sub.2, --CN, or --R.sup.Z6 wherein [0123]
R.sup.Z6 is --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6 is optionally
substituted with at least one R.sup.Z6', [0124] wherein each
R.sup.Z6' is independently -halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, [0125]
wherein R.sup.Z6' is optionally substituted with one or more
R'.
[0126] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0127] B
is pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl,
oxazolidinyl, triazolidinyl, or tetrazolidinyl, wherein [0128] each
carbon is substituted by two R.sup.3 and each nitrogen is
substituted by R.sup.N'; and [0129] each R.sup.N' is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.6)cycloalkyl, -aryl,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl,
-aroyl, -heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0130] R.sup.N' is
optionally substituted with one or more groups which are
independently halogen, --OR.sup.N'', --NR.sup.N''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0131] wherein each R.sup.N'' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
[0132] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0133] B
is pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl,
oxazolidinyl, triazolidinyl, or tetrazolidinyl, wherein [0134] each
carbon is substituted by two R.sup.3 and each nitrogen is
substituted by R.sup.N'; [0135] Y is N; and [0136] ring C contains
2 heteroatoms, and 5 total atoms, wherein [0137] the remaining
heteroatom moiety is O, S, or NR.sup.N1, and the carbon atoms are
each optionally substituted with one or two R.sup.C.
[0138] In another embodiment, the invention provides the compound
according to formula (I), wherein X is N; G is hydrogen; [0139] B
is pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl,
oxazolidinyl, triazolidinyl, or tetrazolidinyl, wherein [0140] each
carbon is substituted by two R.sup.3 and each nitrogen is
substituted by R.sup.N'; [0141] Y is N; and [0142] ring C contains
2 heteroatoms, and 6 total atoms, wherein [0143] the remaining
heteroatom moiety is O, S, or NR.sup.N1, and the carbon atoms are
each optionally substituted with one or two R.sup.C.
[0144] In another embodiment, the invention provides the compound
according to formula (I), wherein X is CR.sup.1.
[0145] In another embodiment, the invention provides the compound
according to formula (I), wherein X is CR.sup.1; and G is --H.
[0146] In another embodiment the invention provides the compound
according to formula (I), wherein X is CR.sup.1; and G is a
heterocycle or --(C.sub.1-C.sub.6)alkyl, each optionally
substituted with at least one group independently selected from the
group consisting of --OR.sup.G, --N(R.sup.G).sub.2, --SR,
--S(O)R.sup.G, --S(O).sub.2R.sup.G, --COOR.sup.G,
--CON(R.sup.G).sub.2, and --(C.sub.1-C.sub.6)alkyl-OR.sup.G,
wherein R.sup.G is hydrogen, --(C.sub.1-C.sub.6)alkyl, or
--C(O)(C.sub.1-C.sub.6)alkyl.
[0147] In another embodiment, the invention provides the compound
according to formula (I), wherein X is CR.sup.1; and G is a
heterocycle or --(C.sub.1-C.sub.6)alkyl, each optionally
substituted with at least one group independently selected from the
group consisting of --OH and --COOH.
[0148] In another embodiment, the invention provides the compound
according to formula (I), wherein X is CR.sup.1; and G is a
tetrahydrofuranyl, tetrahydropyranyl, or --(C.sub.5-C.sub.6)alkyl,
each optionally substituted with at least one group independently
selected from the group consisting of --OH and --COOH.
[0149] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0150] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, [0151] wherein [0152] each R.sup.4is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0153] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0154] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0155] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl.
[0156] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0157] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0158] each R.sup.4is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0159] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0160] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41 ,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0161] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0162] B is aromatic; and
[0163] G.sup.1, G.sup.2, and G.sup.3 are each independently O, N or
CR.sup.3.
[0164] In a preferred embodiment, the invention provides the
compound according to formula (I), wherein G is hydrogen; X is
CR.sup.1, wherein [0165] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2OR, or --S(O).sub.2N(R.sup.4).sub.2,
wherein [0166] each R.sup.4 is independently --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl, [0167]
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein [0168] R.sup.4 is
optionally substituted with at least one group, each of which are
independently halogen, --OH, --(C.sub.1-C.sub.6)alkoxy,
--C(O)R.sup.41, --S(O).sub.2R.sup.41, --OS(O).sub.2R.sup.41,
-cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0169] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0170] B is imidazolyl,
oxazoyl, pyrazoyl, pyrroyl, or isoxazoyl wherein each carbon atom
is substituted by R.sup.3.
[0171] In a more preferred embodiment, the invention provides the
compound according to formula (I), wherein G is hydrogen; X is
CR.sup.1, wherein [0172] R.sup.1 is --N, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0173] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0174] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0175] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0176] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0177] B is imidazolyl
wherein each carbon atom is substituted by R.sup.3; and
[0178] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0179] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0180] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0181] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0182] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0183] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0184] B is imidazolyl
wherein each carbon atom is substituted by R.sup.3; [0185] each
R.sup.3 is independently R.sup.Z3, wherein [0186] R.sup.Z3 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z3 is optionally
substituted with at least one R.sup.Z3', wherein [0187] each
R.sup.Z.sup.3' is independently -halogen, -cyano, --OR, --C(O)OR,
--C(O)R, --C(O)NR.sub.2, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl, or
-heterocycloalkyl.
[0188] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0189] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0190] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0191] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0192] R.sup.4 is optionally substituted with at least one
group, each of which are independently halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0193] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0194] B is imidazolyl
wherein each carbon atom is substituted by R.sup.3; and [0195]
R.sup.2 and R.sup.6 are each --H, -halogen, --NO.sub.2, --CN, or
--R.sup.Z6 wherein [0196] R.sup.Z6 is --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein R.sup.Z6 is optionally substituted with at least one
R.sup.Z6', [0197] wherein each R.sup.Z6' is independently -halogen,
--OR, --C(O)OR, --C(O)R, --(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0198] wherein R.sup.Z6' is
optionally substituted with one or more R'.
[0199] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0200] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0201] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0202] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0203] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0204] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0205] B is imidazolyl
wherein each carbon atom is substituted by R.sup.3; and [0206]
R.sup.N' is --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkanoyl,
--(C.sub.3-C.sub.8)cycloalkyl, -aryl, -heteroaryl,
--(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl, -aroyl,
-heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0207] R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.N''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0208] wherein each R.sup.N'' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy,
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
[0209] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0210] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0211] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0212] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0213] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2OR.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0214] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0215] B is imidazolyl
wherein each carbon atom is substituted by R.sup.3; [0216] Y is N;
and [0217] ring C contains 2 heteroatoms, and 5 total atoms,
wherein [0218] the remaining heteroatom moiety is O, S, or
NR.sup.N1, and the carbon atoms are each optionally substituted
with one or two R.sup.C.
[0219] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0220] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0221] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0222] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0223] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0224] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0225] B is imidazolyl
wherein each carbon atom is substituted by R.sup.3; [0226] Y is N;
and [0227] ring C contains 2 heteroatoms, and 6 total atoms,
wherein [0228] the remaining heteroatom moiety is O, S, or
NR.sup.N1, and the carbon atoms are each optionally substituted
with one or two R.sup.C.
[0229] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0230] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or --S(O).sub.2N(.sup.4).sub.2,
wherein [0231] each R.sup.4 is independently --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl, [0232]
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein [0233] R.sup.4 is
optionally substituted with at least one group, each of which are
independently -halogen, --OH, --(C.sub.1-C.sub.6)alkoxy,
--C(O)R.sup.41, --S(O).sub.2R.sup.41, --OS(O).sub.2R.sup.41,
-cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0234] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0235] B is not aromatic;
and [0236] G.sup.1, G.sup.2, and G.sup.3 are each independently O,
N, CR.sup.3, C(R.sup.3).sub.2, or N(R.sup.N').
[0237] In a preferred embodiment, the invention provides the
compound according to formula (I), wherein G is hydrogen; X is
CR.sup.1, wherein [0238] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0239] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0240] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0241] R.sup.4 is optionally substituted with at least one
group, each of which are independently-halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0242] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0243] B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein [0244] each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'.
[0245] In a more preferred embodiment, the invention provides the
compound according to formula (I), wherein G is hydrogen; X is
CR.sup.1, wherein [0246] R.sup.is --N, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0247] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0248] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0249] R.sup.4is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0250] wherein R.sup.4l is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0251] B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein [0252] each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'; and each R.sup.3 is independently R.sup.Z3, wherein
[0253] R.sup.Z3 is --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein R.sup.Z3 is optionally substituted with at least one
R.sup.Z3', wherein [0254] each R.sup.Z3' is independently -halogen,
-cyano, --OR, --C(O)OR, --C(O)R, --C(O)NR.sub.2,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, or -heterocycloalkyl.
[0255] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0256] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0257] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0258] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0259] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0260] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0261] B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein [0262] each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'; and R.sup.2 and R.sup.6 are each --H, -halogen,
--NO.sub.2, --CN, or --R.sup.Z6 wherein [0263] R.sup.Z6 is
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.3-C.sub.8)cycloalkyl, --(C.sub.1-C.sub.6)alkylaryl,
-heterocycle, -aryl, or -heteroaryl, wherein R.sup.Z6 is optionally
substituted with at least one R.sup.Z6', [0264] wherein each
R.sup.Z6' is independently -halogen, --OR, --C(O)OR, --C(O)R,
--(C.sub.1-C.sub.6)alkyl, or --(C.sub.1-C.sub.6)haloalkyl, [0265]
wherein R.sup.Z6' is optionally substituted with one or more
R'.
[0266] In a preferred embodiment, the invention provides the
compound according to formula (I), wherein G is hydrogen; X is
CR.sup.1, wherein [0267] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0268] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0269] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0270] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0271] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0272] B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein [0273] each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'; and each R.sup.N' is independently --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkanoyl, --(C.sub.3-C.sub.8)cycloalkyl, -aryl,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkanoyl, -heterocycloyl,
-aroyl, -heteroaroyl, --(C.sub.1-C.sub.6)alkoxycarbonyl, or
-aryl(C.sub.1-C.sub.6)alkoxycarbonyl, wherein [0274] R.sup.N' is
optionally substituted with one or more groups which are
independently -halogen, --OR.sup.N'', --NR.sup.''.sub.2,
--NO.sub.2, --CN, --(C.sub.1-C.sub.6)alkyl, -aryl, -heterocycle,
-heteroaryl, --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)haloalkyl, [0275] wherein each R.sup.N'' is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)haloalkyl, --(C.sub.1-C.sub.6)alkoxy, or
--(C.sub.3-C.sub.8)cycloalkyl, -heterocycloalkyl, aryl, or
heteroaryl, wherein the alkyl and alkoxy are optionally substituted
with one or more R'.
[0276] In a more preferred embodiment, the invention provides the
compound according to formula (I), wherein G is hydrogen; X is
CR.sup.1, wherein [0277] R.sup.4 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0278] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0279] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0280] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0281] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0282] B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein [0283] each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'; [0284] Y is N; and [0285] ring C contains 2 heteroatoms,
and 5 total atoms, wherein [0286] the remaining heteroatom moiety
is O, S, or NR.sup.N1, and the carbon atoms are each optionally
substituted with one or two R.sup.C.
[0287] In another embodiment, the invention provides the compound
according to formula (I), wherein G is hydrogen; X is CR.sup.1,
wherein [0288] R.sup.1 is --CN, --NO.sub.2, -halogen,
--C(O)OR.sup.4, --C(O)R.sup.4, --C(O)N(R.sup.4).sub.2,
--S(O)R.sup.4, --S(O).sub.2R.sup.4, or
--S(O).sub.2N(R.sup.4).sub.2, wherein [0289] each R.sup.4 is
independently --H, --(C.sub.1-C.sub.6)alkyl,
--(C.sub.2-C.sub.6)alkenyl, [0290] --(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.6)alkylaryl, -heterocycle, -aryl, or -heteroaryl,
wherein [0291] R.sup.4 is optionally substituted with at least one
group, each of which are independently -halogen, --OH,
--(C.sub.1-C.sub.6)alkoxy, --C(O)R.sup.41, --S(O).sub.2R.sup.41,
--OS(O).sub.2R.sup.41, -cyano, -nitro,--(C.sub.1-C.sub.6)alkyl, or
--(C.sub.1-C.sub.6)haloalkyl, [0292] wherein R.sup.41 is --H,
--(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)haloalkyl,
--(C.sub.1-C.sub.6)alkoxy, --(C.sub.3-C.sub.8)cycloalkyl,
-heterocycloalkyl, aryl, or heteroaryl; [0293] B is pyrrolidinyl,
pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl,
triazolidinyl, or tetrazolidinyl, wherein [0294] each carbon is
substituted by two R.sup.3 and each nitrogen is substituted by
R.sup.N'; [0295] Y is N; and [0296] ring C contains 2 heteroatoms,
and 6 total atoms, wherein [0297] the remaining heteroatom moiety
is O, S, or NR.sup.N1, and the carbon atoms are each optionally
substituted with one or two R.sup.C.
[0298] In another embodiment, the invention provides the compound
according to formula (I), which is
4-(1H-imidazol-2-yl)-2-methyl-5-((4-methylpiperazin-1-yl)methyl)pyridin-3-
-ol.
[0299] In a further aspect, the present invention provides
pharmaceutical compositions comprising one or more compounds of the
invention, as disclosed above and a pharmaceutically acceptable
carrier. Preferred embodiments of the pharmaceutical compositions
are described below.
[0300] In a further aspect, the present invention provides methods
for treating or inhibiting development of one or more AGE- and/or
ALE-associated complications in subject in need thereof comprising
administering one or more compounds or pharmaceutical compositions
of the invention to a subject in need thereof. As used herein, the
phrase "AGE and/or ALE associated complications" includes, but is
not limited to accelerated protein aging, retinopathy, nephropathy,
proteinuria, impaired glomerular clearance, neuropathy,
hyperlipidemia, hypertriglyceridemia, hypercholesterolemia,
atherosclerosis, cardiovascular disease, and neurodegenerative
amyloid diseases, such as Alzheimer's disease, diabetes-associated
hyperlipidemia, oxidative modification of proteins, arthritis,
connective tissue diseases, amyloidosis, urinary stone disease,
obesity-related complications proliferation or smooth muscle cells
in the aorta, coronary artery occlusion, oxidative stress-related
conditions, and hypertension; and dialysis-related disorders
including dialysis-related cardiac morbidity and mortality,
dialysis-related amyloidosis, dialysis-related increases in
permeability of the peritoneal membrane in a dialysis patient,
renal failure progression in a dialysis patient, and inhibiting
ultrafiltration failure and peritoneal membrane destruction in a
dialysis patient.
[0301] In a further aspect, the invention provides methods for
treating or inhibiting development of one or more of diabetic
nephropathy, proteinuria, impaired glomerular clearance,
retinopathy, neuropathy, atherosclerosis, diabetes-associated
hyperlipidemia, oxidative modification of proteins, arthritis,
connective tissue diseases, amyloidosis, urinary stone disease,
obesity-related complications proliferation or smooth muscle cells
in the aorta, coronary artery occlusion, oxidative stress-related
disorders and hypertension; and dialysis-related disorders
including dialysis-related cardiac morbidity and mortality,
dialysis-related amyloidosis, dialysis-related increases in
permeability of the peritoneal membrane in a dialysis patient,
renal failure progression in a dialysis patient, and inhibiting
ultrafiltration failure and peritoneal membrane destruction in a
dialysis patient, wherein the methods comprise administering an
effective amount of one or more compounds of the present invention,
or a pharmaceutically acceptable salt thereof, to a subject in need
of such treatment.
[0302] In a preferred embodiment, the methods are used to treat
patients suffering from hyperlipidemia and/or hyperglycemia or
their complications, or to inhibit development of complications
arising from hyperlipidemia and/or hyperglycemia, such as those
described above.
[0303] While the methods of this aspect of the present invention
are not limited by a specific mechanism, it is believed that the
compounds of the invention are useful in treating or inhibiting
development of these complications based on their ability to
inhibit AGE and/or ALE formation, and thus to inhibit the
development or progression of complications associated with
accumulation of AGEs and/or ALEs.
Definitions
[0304] As used herein, "treat" or "treating" means accomplishing
one or more of the following: (a) reducing the severity of the
disorder; (b) limiting or preventing development of symptoms
characteristic of the disorder(s) being treated; (c) inhibiting
worsening of symptoms characteristic of the disorder(s) being
treated; (d) limiting or preventing recurrence of the disorder(s)
in patients that have previously had the disorder(s); and (e)
limiting or preventing recurrence of symptoms in patients that were
previously symptomatic for the disorder(s).
[0305] As used herein, the term "inhibiting development of" means
to prevent or to minimize development of the disorder or
complication in individuals at risk of developing the disorder or
complication.
[0306] The term "absent" as used herein means the group is replaced
by a single bond. If replacing the group with a bond results in two
connected moieties both defined as bonds, then -bond-bond- groups
are understood to reduce to a single bond.
[0307] The term "alkenyl" as used herein, means a straight or
branched chain hydrocarbon containing from 2 to 10 carbons and
containing at least one carbon-carbon double bond. Representative
examples of alkenyl include, but are not limited to, ethenyl,
2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl,
2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.
[0308] The term "alkoxy" as used herein, means an alkyl group, as
defined herein, appended to the parent molecular moiety through an
oxygen atom. Representative examples of alkoxy include, but are not
limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy,
tert-butoxy, pentyloxy, and hexyloxy.
[0309] The term "alkyl" as used herein, means a straight or
branched chain hydrocarbon containing from 1 to 10 carbon atoms.
Representative examples of alkyl include, but are not limited to,
methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl,
tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl,
2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl,
and n-decyl.
[0310] The term "alkanoyl" as used herein, means an alkyl group, as
defined herein, appended to the parent molecular moiety through a
carbonyl group, as defined herein. Representative examples of
alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl,
2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
[0311] The term "alkoxycarbonyl" as used herein, means an alkoxy
group, as defined herein, appended to the parent molecular moiety
through a carbonyl group, as defined herein. Representative
examples of alkoxycarbonyl include, but are not limited to,
methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
[0312] The term "alkynyl" as used herein, means a straight or
branched chain hydrocarbon group containing from 2 to 10 carbon
atoms and containing at least one carbon-carbon triple bond.
Representative examples of alkynyl include, but are not limited, to
acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and
1-butynyl.
[0313] The term "aryl," as used herein, means phenyl or a bicyclic
aryl or a tricyclic aryl. The bicyclic aryl is naphthyl, or a
phenyl fused to a cycloalkyl, or a phenyl fused to a cycloalkenyl.
The bicyclic aryl is attached to the parent molecular moiety
through any carbon atom contained within the bicyclic aryl.
Representative examples of the bicyclic aryl include, but are not
limited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl,
and tetrahydronaphthalenyl. The tricyclic aryl is anthracene or
phenanthrene, or a bicyclic aryl fed to a cycloalkyl, or a bicyclic
aryl fused to a cycloalkenyl, or a bicyclic aryl filed to a phenyl.
The tricyclic aryl is attached to the parent molecular moiety
through any carbon atom contained within the tricyclic aryl.
Representative examples of tricyclic aryl ring include, but are not
limited to, azulenyl, dihydroanthracenyl, fluorenyl, and
tetrahydrophenanthrenyl.
[0314] The term "arylalkoxycarbonyl" as used herein, means an
arylalkoxy group, as defined herein, appended to the parent
molecular moiety through a carbonyl group, as defined herein.
Representative examples of arylalkoxycarbonyl include, but are not
limited to, benzyloxycarbonyl and naphth-2-ylmethoxycarbonyl.
[0315] The term "arylalkyl" as used herein, means an aryl group, as
defined herein, appended to the parent molecular moiety through an
alkyl group, as defined herein. Representative examples of
arylalkyl include, but are not limited to, benzyl, 2-phenylethyl,
3-phenylpropyl, and 2-naphth-2-ylethyl.
[0316] The term "aroyl" as used herein, means an aryl group, as
defined herein, appended to the parent molecular moiety through a
carbonyl group, as defined herein. Representative examples of
arylcarbonyl include, but are not limited to, benzoyl and
naphthoyl.
[0317] The term "cycloalkyl" as used herein, means a saturated
cyclic hydrocarbon group containing from 3 to 8 carbons, examples
of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, and cyclooctyl.
[0318] The term "cycloalkanoyl" as used herein, means cycloalkyl
group, as defined herein, appended to the parent molecular moiety
through a carbonyl group, as defined herein. Representative
examples of cycloalkylcarbonyl include, but are not limited to,
cyclopropylcarbonyl, 2-cyclobutylcarbonyl, and
cyclohexylcarbonyl.
[0319] The term "halo" or "halogen" as used herein, means --Cl,
--Br, --I or --F.
[0320] The term "haloalkyl" as used herein, means at least one
halogen, as defined herein, appended to the parent molecular moiety
through an alkyl group, as defined herein. Representative examples
of haloalkyl include, but are not limited to, chloromethyl,
2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and
2-chloro-3-fluoropentyl.
[0321] The term "heteroaryl," as used herein, means a monocyclic
heteroaryl or a bicyclic heteroaryl. The monocyclic heteroaryl is a
5 or 6 membered ring. The 5 membered ring consists of two double
bonds and one, two, three or four nitrogen atoms and optionally one
oxygen or sulfur atom. The 6 membered ring consists of three double
bonds and one, two, three or four nitrogen atoms. The 5 or 6
membered heteroaryl is connected to the parent molecular moiety
through any carbon atom or any nitrogen atom contained within the
heteroaryl. Representative examples of monocyclic heteroaryl
include, but are not limited to, furyl, imidazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl,
pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl,
thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl. The
bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a
phenyl, or a monocyclic heteroaryl fused to a cycloalkyl, or a
monocyclic heteroaryl fused to a cycloalkenyl, or a monocyclic
heteroaryl fed to a monocyclic heteroaryl. The bicyclic heteroaryl
is connected to the parent molecular moiety through any carbon atom
or any nitrogen atom contained within the bicyclic heteroaryl.
Representative examples of bicyclic heteroaryl include, but are not
limited to, benzimidazolyl, benzofuranyl, benzothienyl,
benzoxadiazolyl, cinnolinyl, dihydroquinolinyl,
dihydroisoquinolinyl, furopyridinyl, indazolyl, indolyl,
isoquinolinyl, naphthyridinyl, quinolinyl, tetrahydroquinolinyl,
and thienopyridinyl.
[0322] The term "heteroaryloyl" as used herein, means a heteroaryl
group, as defined herein, appended to the parent molecular moiety
through a carbonyl group, as defined herein. Representative
examples of heteroarylcarbonyl include, but are not limited to,
fur-3-ylcarbonyl, 1H-imidazol-2-ylcarbonyl,
1H-imidazol-4-ylcarbonyl, pyridin-3-ylcarbonyl,
6-chloropyridin-3-ylcarbonyl, pyridin-4-ylcarbonyl,
(6-(trifluoromethyl)pyridin-3-yl)carbonyl,
(6-(cyano)pyridin-3-yl)carbonyl, (2-(cyano)pyridin-4-yl)carbonyl,
(5-(cyano)pyridin-2-yl)carbonyl, (2-(chloro)pyridin-4-yl)carbonyl,
pyrimidin-5-ylcarbonyl, pyrimidin-2-ylcarbonyl, thien-2-ylcarbonyl,
and thien-3-ylcarbonyl.
[0323] The term "heterocycle" as used herein, means a monocyclic,
and 3, 4, 5, 6 or 7 membered ring containing at least one
heteroatom independently selected from the group consisting of O,
N, and S. The 3 or 4 membered ring contains 1 heteroatom selected
from the group consisting of O, N and S. The 5 membered ring
contains zero or one double bond and one, two or three heteroatoms
selected from the group consisting of O, N and S. The 6 or 7
membered ring contains zero, one or two double bonds and one, two
or three heteroatoms selected from the group consisting of O, N and
S. The heterocycle is connected to the parent molecular moiety
through any carbon atom or any nitrogen atom contained within the
monocyclic heterocycle. Representative examples of heterocycles
include, but are not limited to, azetidinyl, azepanyl, aziridinyl,
diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl,
1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl,
isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl,
oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl,
piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl,
pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl,
thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl,
thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine
sulfone), thiopyranyl, and trithianyl.
[0324] The term "heterocycloyl" as used herein, means a
heterocycle, as defined herein, appended to the parent molecular
moiety through a carbonyl group, as defined herein.
[0325] "Oxidative stress" is defined as specific increases in
reactive oxygen species and derived free radicals. Oxidative-stree
related conditions include, but are not limited to atherosclerosis,
ischemia-reperfusion injury, inflammatory diseases such as
arthritis, cancer, exposure to ionizing radiation and/or
chemotherapeutic agents, pulmonary adult respiratory distress
syndrome (ARDS), myocardial infarction and strokes, pancreatitis,
or intestinal ulceration, and aging. (See, for example, U.S. Pat.
Nos. 5,700,654 and 5,462,946).
[0326] The term "oxide" as used herein, means an --O moiety; for
example, attachment of an oxide group to a nitrogen forms an
N-oxide compound, as is familiar to those skilled in the art. In
such compounds, the oxygen has a formal negative charge and the
nitrogen has a formal positive charge, therefore, the entire
compound has a zero net charge.
[0327] The term "oxo" as used herein, means an .dbd.O moiety.
Pharmaceutical Compositions and Administration
[0328] The instant compounds can be administered individually or in
combination, usually in the form of a pharmaceutical composition.
Such compositions are prepared in a manner well known in the
pharmaceutical art and comprise at least one active compound.
[0329] The compounds of the invention can be administered as the
sole active pharmaceutical agent, or they can be used in
combination with one or more other compounds useful for carrying
out the methods of the invention, including but not limited to
pyridoxamine, aminoguanidine, compounds disclosed in WO 2004/019889
(including but not limited to BST 4996, BST 4997, and BST-146;
agents that promote glycemic control, such as insulin, metformin,
and thiazolidinediones; and anti-hypertensives such as angiotensin
converting enzyme inhibitors (ACED, angiotensin II receptor
blockers (ARB), endothelin receptor antagonists and rennin
inhibitors. When administered as a combination, the therapeutic
agents can be formulated as separate compositions that are given at
the same time or different times, or the therapeutic agents can be
given as a single composition.
[0330] The compounds may be made up in a solid form (including
granules, powders or suppositories) or in a liquid form (e.g.,
solutions, suspensions, or emulsions). The compounds of the
invention may be applied in a variety of solutions and may be
subjected to conventional pharmaceutical operations such as
sterilization and/or may contain conventional adjuvants, such as
preservatives, stabilizers, wetting agents, emulsifiers, buffers
etc.
[0331] The compounds of the invention may be administered orally,
topically, parenterally, by inhalation or spray or rectally in
dosage unit formulations containing conventional non-toxic
pharmaceutically acceptable carriers, adjuvants and vehicles. The
term parenteral as used herein includes percutaneous, subcutaneous,
intravascular (e.g., intravenous), intramuscular, or intrathecal
injection or infusion techniques and the like. In addition, there
is provided a pharmaceutical formulation comprising a compound of
the invention and a pharmaceutically acceptable carrier. One or
more compounds of the invention may be present in association with
one or more non-toxic pharmaceutically acceptable carriers and/or
diluents and/or adjuvants, and if desired other active ingredients.
The pharmaceutical compositions containing compounds of the
invention may be in a form suitable for oral use, for example, as
tablets, troches, lozenges, aqueous or oily suspensions,
dispersible powders or granules, emulsion, hard or soft capsules,
or syrups or elixirs.
[0332] Compositions intended for oral use may be prepared according
to any method known to the art for the manufacture of
pharmaceutical compositions and such compositions may contain one
or more agents selected from the group consisting of sweetening
agents, flavoring agents, coloring agents and preservative agents
in order to provide palatable preparations. Tablets contain the
active ingredient in admixture with non-toxic pharmaceutically
acceptable excipients that are suitable for the manufacture of
tablets. These excipients may be for example, inert diluents, such
as calcium carbonate, sodium carbonate, lactose, calcium phosphate
or sodium phosphate; granulating and disintegrating agents, for
example, corn starch, or alginic acid; binding agents, for example
starch, gelatin or acacia, and lubricating agents, for example
magnesium stearate, stearic acid or talc. The tablets may be
uncoated or they may be coated by known techniques. In some cases
such coatings may be prepared by known techniques to delay
disintegration and absorption in the gastrointestinal tract and
thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monosterate or
glyceryl distearate may be employed.
[0333] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin or olive oil.
[0334] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone,
gum tragacanth and gum acacia; dispersing or wetting agents may be
a naturally-occurring phosphatide, for example, lecithin, or
condensation products of an alkylene oxide with fatty acids, for
example polyoxyethylene stearate, or condensation products of
ethylene oxide with long chain aliphatic alcohols, for example
heptadecaethyleneoxycetanol, or condensation products of ethylene
oxide with partial esters derived from fatty acids and a hexitol
such as polyoxyethylene sorbitol monooleate, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and hexitol anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions may also contain one or more
preservatives, for example ethyl, or n-propyl p-hydroxybenzoate,
one or more coloring agents, one or more flavoring agents, and one
or more sweetening agents, such as sucrose or saccharin.
[0335] Oily suspensions may be formulated by suspending the active
ingredients in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
and flavoring agents may be added to provide palatable oral
preparations. These compositions may be preserved by the addition
of an anti-oxidant such as ascorbic acid.
[0336] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents or suspending agents are exemplified by those
already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, may also be present.
[0337] Pharmaceutical compositions of the invention may also be in
the form of oil-in-water emulsions. The oily phase may be a
vegetable oil or a mineral oil or mixtures of these. Suitable
emulsifying agents may be naturally-occurring gums, for example gum
acacia or gum tragacanth, naturally-occurring phosphatides, for
example soy bean, lecithin, and esters or partial esters derived
from fatty acids and hexitol, anhydrides, for example sorbitan
monooleate, and condensation products of the said partial esters
with ethylene oxide, for example polyoxyethylene sorbitan
monooleate. The emulsions may also contain sweetening and flavoring
agents.
[0338] Syrups and elixirs may be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol, glucose or
sucrose. Such formulations may also contain a demulcent, a
preservative and flavoring and coloring agents. The pharmaceutical
compositions may be in the form of a sterile injectable aqueous or
oleaginous suspension. This suspension may be formulated according
to the known art using those suitable dispersing or wetting agents
and suspending agents that have been mentioned above. The sterile
injectable preparation may also be a sterile injectable solution or
suspension in a non-toxic parentally acceptable diluent or solvent,
for example as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that may be employed are water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose any bland fixed oil may be
employed including synthetic mono-or diglycerides. In addition,
fatty acids such as oleic acid find use in the preparation of
injectables.
[0339] The compounds and pharmaceutical compositions of the present
invention may also be administered in the form of suppositories,
e.g., for rectal administration of the drug. These compositions can
be prepared by mixing the drug with a suitable non-irritating
excipient that is solid at ordinary temperatures but liquid at the
rectal temperature and will therefore melt in the rectum to release
the drug. Such materials include cocoa butter and polyethylene
glycols.
[0340] Compounds and pharmaceutical compositions of the present
invention may be administered parenterally in a sterile medium. The
drug, depending on the vehicle and concentration used, can either
be suspended or dissolved in the vehicle. Advantageously, adjuvants
such as local anesthetics, preservatives and buffering agents can
be dissolved in the vehicle.
[0341] Dosage levels of the order of from about 0.01 mg to about 50
mg per kilogram of body weight per day, more preferably between 0.1
mg to about 50 mg per kilogram of body weight per day, and even
more preferably between about 0.1 mg to about 20 mg per kilogram of
body weight per day are useful in the treatment of the
above-indicated conditions. The amount of active ingredient that
may be combined with the carrier materials to produce a single
dosage form will vary depending upon the host treated and the
particular mode of administration. Dosage unit forms will generally
contain between from about 1 mg to about 500 mg of an active
ingredient.
[0342] Pharmaceutical compositions containing the compounds
described herein are administered to an individual in need thereof.
In a preferred embodiment, the subject is a mammal; in a more
preferred embodiment, the subject is a human. In therapeutic
applications, compositions are administered in an amount sufficient
to carry out the methods of the invention. Amounts effective for
these uses depend on factors including, but not limited to, the
nature of the compound (specific activity, etc.), the route of
administration, the stage and severity of the disorder, the weight
and general state of health of the subject, and the judgment of the
prescribing physician. The active compounds are effective over a
wide dosage range. However, it will be understood that the amount
of the compound actually administered will be determined by a
physician, in the light of the above relevant circumstances.
Therefore, the above dosage ranges are not intended to limit the
scope of the invention in any way.
[0343] For administration to non-human mammals, the composition may
also be added to the animal feed or drinking water. It may be
convenient to formulate these animal feed and drinking water
compositions so that the animal ingests an appropriate quantity of
the composition during a meal or throughout the course of the day.
It may also be convenient to present the composition as a premix
for addition to the feed or drinking water.
Preparation of Compounds of the Invention
[0344] The compounds and processes of the present invention will be
better understood in connection with the following synthetic
schemes which illustrate the methods by which the compounds of the
invention may be prepared. Starting materials can be obtained from
commercial sources or prepared by well-established literature
methods known to those of ordinary skill in the art.
[0345] The reactions are performed in a solvent appropriate to the
reagents and materials employed and suitable for the
transformations being effected. It will be understood by those
skilled in the art of organic synthesis that the functionality
present on the molecule should be consistent with the
transformations proposed. This will sometimes require a judgment to
modify the order of the synthetic steps or to select one particular
process scheme over another in order to obtain a desired compound
of the invention.
[0346] It will also be recognized that another major consideration
in the planning of any synthetic route in this field is the
judicious choice of the protecting group used for protection of the
reactive functional groups present in the compounds described in
this invention. An authoritative account describing the many
alternatives to the trained practitioner is Greene and Wuts
(Protective Groups In Organic Synthesis, Wiley and Sons, 1999).
Suitable protecting groups include, but are not limited to,
tert-butoxycarbonyl (BOC), trimethylsilylethanesulfonamide (SES),
benzyloxycarbonyl (CBZ) and benzyl (Bn) protecting groups.
##STR5##
[0347] One possible procedure to prepare compounds of the invention
is shown in Scheme 1. Imidazole compounds (003, R.sup.N'.dbd.H) are
synthesized by reaction of .alpha.-diketones (002) with pyridoxal
hydrochloride (001) and a source of ammonia (NH.sub.4OAc). If a
primary amine (R.sup.N'--NH.sub.2) is included in the reaction, the
N-functionalized product is formed. The hydroxymethyl of 003 is
converted to the halomethyl derivative (004) with SOCl.sub.2
(X'.dbd.Cl). Alternatively, reagents such as POCl.sub.3, PCl.sub.5,
PCl.sub.3, PPh.sub.3 and CCl.sub.4 (X'.dbd.Cl); SOBr.sub.2,
PPh.sub.3 and CBr.sub.4, PPh.sub.3 and Br.sub.2 (X'.dbd.Br); and
PPh.sub.3 and I.sub.2 or N-iodosuccinimide (X'.dbd.I) may be
utilized. Subsequently, the substitution of the halomethyl
derivative (004) with a cyclic amine yields 005. If the imidazole
nitrogen is unsubstituted (005, R.sup.N'.dbd.H), it may be further
substituted by reaction with a reagent of the form R.sup.N'--X' or
R.sup.N'--O--R.sup.N' to yield compound 006. Examples of
appropriate reagents include, but are not limited to CH.sub.3I,
CF.sub.3CH.sub.2I, HOCH.sub.2CH.sub.2Br, CH.sub.3(CO)Cl,
(CF.sub.3CO)O(COCF.sub.3), (PhCO)O(COPh), and the like.
##STR6##
[0348] .alpha.-Diketones (002, Scheme 1) can be prepared by methods
familiar to those skilled in the art. A few techniques are
summarized in Scheme 2, involving one or two step procedures. The
desired .alpha.-diketones may be prepared directly from alkenes by
reaction with reagents such as KMnO.sub.4 in the presence of acetic
anhydride or cupric sulfate. Alternatively, alkynes may be utilized
with reagents such as KMnO.sub.4 in the presence of acetic acid or
NaHCO.sub.3 with MgSO.sub.4; H.sub.2O.sub.2 and MeReO.sub.3; NaOCl
or NaIO.sub.4 and catalytic RuO.sub.2; or PhIO and
RuCl.sub.2(PPh.sub.3).sub.2. In two steps, symmetric or asymmetric
(where two different aldehydes with different R.sup.3 groups are
used) .alpha.-diols (0021) may be prepared from the corresponding
aldehydes through the pinacol reaction. Appropriate reagents for
the pinacol reaction include, but are not limited to Li, Na,
TiCl.sub.3, Zn and HCl, and SmI.sub.2. The .alpha.-diols (0021) may
oxidized to the corresponding .alpha.-diketone (002) with acetic
anhydride or trifluoroacetic anhydride in DMSO; or with NaOCl and
catalytic 4-methoxy-2,2,6,6-tetramethyl-1-piperidinyloxy, free
radical (4-methoxy-TEMPO).
EXAMPLE 1
4-(4,5-Diethyl-1H-imidazol-2-yl)-5-hydroxymethyl-2-methyl-pyridin-3-ol
[0349] ##STR7##
[0350] Pyridoxal hydrochloride (2.03 g, 10 mmol) was dissolved in
MeOH (25 mL) and cooled to 0-5.degree. C. 3,4-Hexanedione (8.4 mL,
70 mmol) was added at 0-5.degree. C. and then aq. ammonium
hydroxide solution (25%, 8 mL) keeping the temperature between
5-10.degree. C. The reaction mixture was warmed to rt and stirred
over a period of 15 h. The suspension was filtered and the filtrate
was evaporated to distill off MeOH. Water (10 mL) was added and
extracted with ethyl acetate (4.times.15 mL). The combined organic
layers were washed with water (10 mL), brine (10 mL), dried over
Na.sub.2SO.sub.4 (5 g) and evaporated to dryness. The residue was
suspended in ethyl acetate (10 mL) and diethyl ether (20 mL) and
stirred for 30 min. The suspension was filtered off, washed with
diethyl ether (20 mL) and dried to give the title compound (920 mg)
as yellow crystals.
EXAMPLE 2
4-(4,5-Diphenyl-1H-imidazol-2-yl)-5-hydroxymethyl-2-methyl-pyridin-3-ol
[0351] ##STR8##
[0352] Benzil (2.10 g, 10 mmol), ammonium acetate (11.5 g, 150
mmol) were dissolved in DMSO (60 mL) and heated to 100.degree. C.
Pyridoxal hydrochloride (4.1 g, 20 mmol) in DMSO (50 mL) was added
drop wise and after 100 min stirring at 100.degree. C. the reaction
mixture was poured into icewater (300 mL) and aq. ammonium
hydroxide solution (50 mL). The precipitate was filtered off,
washed with water (100 mL), dissolved in ethyl acetate (150 mL) and
extracted with water (2.times.50 mL). The organic layer was dried
over MgSO.sub.4(10 g) and evaporated to dryness. The residue was
purified by flash chromatography on silica gel eluting with
toluene/acetone 7/3. Fractions containing product were evaporated
to a volume of 50 mL and cooled to 0.degree. C. The precipitate was
filtered off and dried to give (250 mg) the title compound as a
yellow solid.
EXAMPLE 3
4-[4,5-Bis-(4-fluoro-phenyl)-1H-imidazol-2-yl)-5-hydroxymethyl-2-methyl-py-
ridin-3-ol
[0353] ##STR9## 4,4'-Difluorobenzil (2.46 g, 10 mmol), ammonium
acetate (11.5 g, 150 mmol) were dissolved in DMSO (60 mL) and
heated to 100.degree. C. Pyridoxal hydrochloride (6.1 g, 30 mmol)
in DMSO (50 mL) was added drop wise over a period of 40 min. The
reaction mixture was cooled to rt and poured into icewater (300 mL)
and aq. ammonium hydroxide solution (50 mL). The precipitate was
filtered off, washed with water (100 mL), dissolved in ethyl
acetate (150 mL) and extracted with water (2.times.50 mL). The
organic layer was dried over MgSO.sub.4 (10 g) and evaporated to
dryness. The residue was purified by flash chromatography on silica
gel eluting with toluene/acetone 7/3. Fractions containing product
were evaporated to a volume of 50 mL and cooled to 0.degree. C. The
precipitate was filtered off and dried to give (250 mg) the title
compound as a yellow solid.
EXAMPLE 4
4-(4,5-Di-furan-2-yl-1H-imidazol-2-yl)-5-hydroxymethyl-2-methyl-pyridin-3--
ol
[0354] ##STR10##
[0355] .alpha.-Fluril (1.90 g, 10 mmol), ammonium acetate (11.5 g,
150 mmol) were dissolved in DMSO (60 mL) and heated to 100.degree.
C. Pyridoxal hydrochloride (6.1 g, 30 mmol) in DMSO (50 mL) was
added drop wise over a period of 35 min. The reaction mixture was
cooled to it and poured into icewater (300 mL) and aq. ammonium
hydroxide solution (50 mL). The precipitate was filtered off,
washed with water (100 mL), dissolved in ethyl acetate (3.times.200
mL) and extracted with water (50 mL). The organic layer was dried
over MgSO.sub.4 (5 g) and evaporated to dryness. The residue was
purified by flash chromatography on silica gel eluting with
toluene/acetone 7/3. Fractions 13-18 were evaporated to a volume of
20 mL, the precipitate was filtered off and dried to give (170 mg)
a light beige solid. Fractions 19-44 were evaporated to a volume of
20 mL, the precipitate was filtered off and dried to give (320 mg)
the title compound as a light beige solid.
EXAMPLE 5
5-(Chloromethyl)-4-(1H-imidazol-2-yl)-2-methyl-pyridin-3-ol
hydrochloride
[0356] ##STR11##
[0357] 5-(hydroxymethyl)-4-(1H-imidazol-2-yl)-2-methylpyridin-3-ol
(5.1 g, 25 mmol) was suspended in toluene (100 mL) and thionyl
chloride (25 mL) was added. The suspension was heated to reflux for
2 h, cooled to 0.degree. C. and filtered. The title compound was
obtained as brown solid (Purity by NMR: 70-80%) and was used
without further purification in the next step.
EXAMPLE 6
4-(1H-Imidazol-2-yl)-2-methyl-5-[(4-methyl-1-piperazinyl)methyl-pyridin-3--
ol
[0358] ##STR12##
[0359] 5-(chloromethyl)-4-(1H-imidazol-2-yl)-2-methylpyridin-3-ol
hydrochloride (591 mg, 2 mmol) was suspended in methylene chloride
(25 mL) and N-methyl piperazine (2.2 mL, 20 mmol) was added. After
20 h stirring at rt, the reaction mixture was evaporated to
dryness. The residue was purified twice by chromatography on silica
gel eluting with methylene chloride/methanol 9/1. The title
compound (150 mg) was obtained as red brown oil.
EXAMPLE 7
5-(hydroxymethyl)-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-pyridin-3-ol
[0360] ##STR13##
[0361] 5-(hydroxymethyl)-4-(1H-imidazol-2-yl)-2-methylpyridin-3-ol
(1.03 g, 5.0 mmol) was suspended in DMF (50 mL) and methyl iodide
(0.31 mL, 5 mmol) was added at rt. The reaction mixture was stirred
over a period of 19 h and a further portion of methyl iodide (0.125
mL, 2 mmol) was added and stirred over a period of 23 h. Aq.
K.sub.2CO.sub.3 solution (10 mL) and water (50 mL) was added and
extracted with ethyl acetate (2.times.50 mL). Combined organic
layers were dried over MgSO.sub.4 (10 g) and evaporated to a volume
of 20 mL. After 3 days at room temperature, the crystallized
product was filtered off and dried to give (600 mg) the title
compound as a light beige solid.
EXAMPLE 8
Redox Metal Ion Binding Affinity (Cu and Fe)
[0362] The AGE inhibition by these types of compounds is believed
to occur when the compounds interfere with the role of the required
redox metal ions in the oxidative breakdown of the Amadori
intermediates to advanced glycation end products ("glycoxidation").
We have measured the affinity of the compounds for cupric, ferrous
and ferric ions in several cases by following visible spectroscopic
changes. These spectral titrations usually involve adding varying
amounts of compound to a fixed amount of metal ion in a suitable
buffer having low metal ion affinity under physiological pH
conditions. In cases of extreme affinity, binding constants were
estimated in a competitive assay mode. Table 1 provides some data
that has been obtained in this way.
[0363] It will be noted that BST-605 is superior to BST-4997 in
this regard, and the latter compound was superior to pyridoxainine.
The N-methylpiperazine side-chain of BST-4997 thus unexpectedly
enhanced the metal ion binding affinity, which could not have been
predicted a priori.
[0364] Binding affinity is measured as the dissociation constants
K.sub.d (units of concentration). All measurements were done by
visible spectroscopy by monitoring the spectrum of the complex
formed by each compound near its wavelength maximum, which depends
on the metal ion being studied. All Fe wavelengths were 480 nm
except for 430 nm for pyridoxamine. TABLE-US-00001 TABLE 1
Cu.sup.2+ K.sub.d Fe.sup.2+ K.sub.d Fe.sup.3+ K.sub.d Compound
(.mu.M) (mM) (mM) Pyridoxamine 39 +/- 15 49 +/- 9 59 +/- 13
BST-4997 1.13 +/- 0.09 0.69 +/- 0.13 0.61 +/- 0.09 BST-605 0.13 +/-
0.04 0.72 +/- 0.14 0.52 +/- 0.04 C-14547 7.01 +/- 1.69 BST-4996
0.59 +/- 0.11
EXAMPLE 9
AGE Inhibition Efficacy In Vitro
[0365] Using a novel modification of the AGE Inhibition assay, we
have determined the post-Amadori AGE inhibition potency for
compounds of interest. The experiments were designed to determine
the half-maximal inhibitory concentration of compounds ("IC50
values") for inhibiting the conversion of Amadori intermediates to
advanced glycation end products. The post Amadori AGE/CML ELISA
assay has been developed to a 384 well format for rapidly testing
potential inhibitors prepared from DMSO stocks. Assay signal to
background ratios are high, at greater than 20:1. Results in this
format for AGE inhibitors agree well with previous data, providing
some measure of method validation, making the assay is robust and
reliable. Compounds for testing were dissolved at 100 mM or their
maximum concentration in 100% DMSO. 100 mM is the DMSO stock
concentration necessary to detect potential inhibitors that have an
effective concentration similar to that of pyridoxamine. A subset
of compounds were not fully soluble in DMSO at concentrations as
low as 10 mM. Due to low aqueous solubility, an initial screening
of compounds was usually carried out in dilute form across a 100
fold concentration range. Tested concentrations were from 0.2-20
.mu.M to 2-200 .mu.M, with the compound concentration tested being
dependent upon the original solubility in DMSO. When necessary, the
activity of compounds was subsequently confirmed in a more thorough
repeat test against AGE formation from both RNase Amadori and BSA
Amadori. Typically, from DMSO stocks, two stock plates were made.
Each well contained 50 .mu.L.
[0366] The stock plate #2 was then frozen at -20 .degree. C. during
preparation. Later, stock plate #2 was removed from the freezer and
allowed to thaw for 30 minutes. The compounds in the plate were
then mixed repeatedly with a pipettor and diluted 5.times. into
0.01 N HCl in H.sub.2O.
[0367] Further dilutions were then carried out spanning two orders
of magnitude of concentration. After the compounds were diluted, 10
ul of phosphate buffer was added to each well and mixed to
neutralize the solution before protein addition. Next 15 .mu.L of
0.333 mg/mL of RNase-Amadori in phosphate buffer was added from a
stock of ribose-RNAse prepared at 10.7 mg/mL. These constitute the
AGE reaction mixtures. All AGE reactions proceeded for 20 hours at
37.degree. C. Reactions were then diluted 50 fold into coating
buffer by 10.times. then 5.times. serial dilution. Coating
proceeded at 37.degree. C. for two hours. Final protein was 0.1
.mu.g/well in 384 well plates (2 .mu.g/mL). ELISA was carried out
similarly to before using the primary antibody BST-3CK at 1:10000
dilution, and the secondary antibody labeled with DELPHIA Europium
GAR at 1:4000 dilution.
[0368] Pyridoxamine served as a reference to highlight the potency
of BST-4997. In the present instance, the latter compound now
serves as reference to highlight the unanticipated greater potency
of BST-605. Comparative data are given in Table 2 below. The
unexpected 6-fold potency of BST-605 over BST-4997 (and 50-fold
over pyridoxamine) contrasts with the observation that the 5'-amino
derivative C-14547 as well as the 5'-acetamido derivative C-14521
had significantly weaker activity than BST-4997. Thus introducing
the nitrogen at the 5'-position in itself does not account for the
enhanced activity. The heterocyclic piperazine ring thus provides
the key to the enhancement, and we anticipate other similar rings
would be advantageous. TABLE-US-00002 TABLE 2 Potency Relative
Compound IC.sub.50 to BST-4997 Pyridoxamine .sup. 5 mM 0.12
BST-4997 0.6 mM (1) C-14521 2-3 mM 0.2-0.3 C-14547 1-2 mM 0.3-0.6
BST-605 0.1 mM 6
EXAMPLE 10
Cell Based Toxicity Assay
[0369] Hepatotoxicity is one of the major causes of drug failure in
the clinic. HepG2 cells are human cells derived from a liver tumor,
and express many of the proteins and detoxification pathways of
normal hepatocytes, and so make a reasonable model for initial
cellular toxicity testing of candidate compounds. The test is based
on the active conversion of 3-[4,5
dimethylthiazol-2-yl]-2,5-dephenyltetrazolium bromide (MTT) by
mitochondrial oxidation-reduction reactions into blue formazan
crystals. Decreased crystal formation corresponds to decreased cell
viability. Azide and chlorpromazine served as a positive controls
Need: [0370] 10.times. MTT stock solution (5 mg/ml MTT in 0.9%
NaCl) [0371] 0.04 N HCl in isopropanol [0372] Compound stocks: 100
mM in 100% DMSO [0373] MTT working solution: diluting 10.times. MTT
stock into culture medium. Test article in cell culture medium;
Final DMSO concentration on the cells varies with the compound
concentration (Final concentration of solvents such as DMSO should
be kept at or below 1%) Method:
[0374] 1. Aspirate culture medium from HepG2cells. Replace cuture
medium with test article dissolved in culture medium.
[0375] 2. Incubate in 37.degree. C., 5% CO.sub.2 incubator for
16-24 hours.
[0376] 3. Aspirate the medium from the cells; replace with an equal
volume of 37.degree. C. MTT working solution.
[0377] 4. Incubate for 3 hours.
[0378] 5. Replace MTT solution with an equal volume of acidified
isopropanol.
[0379] 6. Place solution in the refrigerator for 12-24 hours.
[0380] 7. Place solution on an orbital shaker to dissolve any
fomazan precipitate.
[0381] 8. Read the absorbance of the solution at 570 nm.
[0382] Several of the compounds of interest were tested at several
concentrations for potential acute toxicity in the HepG2 cell-based
assay system. FIGS. 2 and 3 summarize the results of the assay; in
all these graphs, cell viability increases with bar height.
[0383] FIG. 2 provides comparative data for pyridoxainine (PM),
BST-4997 (also, the free base of this compound which is referred to
as BST-998), a 5'-acetyl ester of BST-4997 (BST-146) which is
rapidly hydrolyzed to the parent, and BST-605.
[0384] At a fixed concentration (1 mM), it was observed that
BST-605 shows no acute toxicity in this assay, whereas BST-4997
shows some evidence of toxicity.
EXAMPLE 11
Maximum Tolerated Dose (MTD) Safety Study in Mice
[0385] A seven day repeat oral gavage study was carried out in male
mice in order to detect any obvious signs of clinical toxicity upon
administration of BST-605. For comparison, two groups were dosed
with BST-4997 and BST-146 (acetyl ester of BST-4997 that is rapidly
hydrolyzed to parent BST-4997). Dosing was done daily at 10, 30 and
100 mg/kg/day, and blood draws were taken at the end of study at 1,
2, 4 and 8 h post-dosing.
[0386] The results confirmed that BST-4997 dosed animals suffered
significant toxicity at and above 30 mg/kg/day, leading to
significant loss of the animals. In contrast, no adverse clinical
signs or gross examination findings were noted for any mice in the
BST-605 dose groups. BST-605 thus possesses marked superiority over
BST-4997 with regard to in vivo toxicity and represents a
significant advance.
EXAMPLE 12
In vivo Plasma Concentration and Metabolites
[0387] The plasma drawn from the mice in the above MTD study was
examined by an HPLC fluorescence method for the presence of parent
drug at different times as well as for the possible presence of
metabolites. A similar examination was done for plasma samples from
the fewer surviving mice that received BST-4997. An HPLC
fluorescence method was developed to assay for parent drugs and
possible metabolites of each drug. The HPLC method was further
adapted for LC-MS/MS study by changing from phosphoric acid to
volatile 20 mM ammonium acetate. Parent drugs were detected and
quantified, and the plasma concentration that was proportional to
dose for BST-605 though not for BST-4997. This indicates improved
pharmacokinetic behavior for BST-605.
[0388] Novel metabolites were detected and quantified for BST-605
and BST-4997, and their retention times and "concentrations"
(assuming similar fluorescence to parents) were measured. Analysis
of such metabolites indicated that the parent compound had been
oxidized and/or undergone glucuronidation. Possible structures for
the metabolites include the following: ##STR14##
EXAMPLE 13
Efficacy Study in STZ Rat Model of Diabetic Neuropathy
[0389] In vivo, BST-605 ameliorates diabetic complications in a STZ
rat model in proportion to its potency in the post-Amadori AGE
inhibition assay. The STZ rat model has been described previously
in WO 2004/019889. Our aim was to ascertain whether BST-605
treatment could correct nerve dysfunction in streptozotocin
(STZ)-diabetic rats. Animals were made diabetic for 6 weeks,
following which they were treated (n=6) for 2 weeks with BST-605
given in the drinking water at concentrations adjusted to
correspond to doses of 0.22, 0.67 and 2.0 mg/kg/day. They were
compared to control non-diabetic rats (n=10).
[0390] FIG. 3 provides the dose-response curve for restoration of
nerve conduction velocity in motor (sciatic nerve) neurons,
demonstrating efficacy at very low concentrations. Motor NCV was
tested between the sciatic notch and knee for the nerve branch to
tibialis anterior muscle, as described in Cameron et al., Q. J.
Exp. Physiol. 74: 917-926 (1989); and Cameron et al., Exp. Neurol.
92: 757-761 (1986).
[0391] FIG. 4 provides the dose-response curve for restoration of
nerve conduction velocity in sensory (saphenous) neurons,
demonstrating efficacy at very low concentrations. Saphenous
sensory NCV was measured between the groin and ankle.
[0392] FIG. 5 compares BST-605 to BST-4997 and pyridoxamine showing
the progression in increased potency that follows the progression
in post-Amadori AGE inhibition.
[0393] We have further established a causal the link between
administration of such post-Amadori AGE inhibitors and therapeutic
benefit by observing that BST-4997 treated STZ rats demonstrated an
actual decrease in AGE levels in the nerve vasculature. This was
done by quantitative measurements of tissue staining for
carboxymethyllysine (CML) AGEs, using anti-CML antibodies. A
significant decrease in AGE staining was observed for animals
treated with BST-4997 as compared to diabetic controls.
[0394] A determination of drug exposure was also made from plasma
collected from STZ rats at sacrifice that were dosed at the lowest
two doses. Drug exposure was observed and measured for BST-605, and
its major metabolites were detected. The detection of parent drugs
and metabolites in the STZ rat, as in the mice plasma, confirms
that sufficient exposure to the drug occurred in the studies so as
to make the toxicity findings and in vivo efficacy reflective of
drug administration.
[0395] It is understood that the foregoing detailed description and
accompanying Examples are merely illustrative and are not to be
taken as limitations upon the scope of the invention, which is
defined by the appended claims. Various changes and modifications
to the disclosed embodiments will be apparent to those skilled in
the art. Such changes and modifications, including without
limitation those relating to the chemical structures, substituents,
derivatives, intermediates, syntheses, formulations and/or methods
of use of the invention, may be made without departing from the
spirit and scope thereof.
* * * * *